Silicon opens laboratory facilities in San Diego
The combined offices and laboratories will allow the company to leverage the capabilities of the DEPArray system in the recovery of single pure cells by offering a rare
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The harmful active pharmaceutical ingredients include diclofenac sodium and methocarbamol. Reumofan Plus, labeled in Spanish, is used for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions.